Marijuana Extract Doesn't Reduce Postoperative Nausea and Vomiting
Article ID: 640940
Released: 6-Oct-2015 10:30 AM EDT
Source Newsroom: Wolters Kluwer Health: Lippincott Williams and Wilkins
Newswise — October 6, 2015 – The marijuana extract tetrahydrocannabinol (THC) isn't effective in preventing nausea and vomiting after surgery in patients at high risk of this common complication, reports a study in Anesthesia & Analgesia.
Intravenous THC had a "negligible" effect on postoperative nausea and vomiting (PONV), as well as "unpredictable psychotropic and sedative side effects," according to the clinical trial by Dr. Lorenz G. Theiler and colleagues of University of Bern, Switzerland. At a time of growing interest in the uses of medical marijuana, the results suggest that marijuana compounds (cannabinoids) aren't a good option to prevent PONV.
No Benefit of Medical Marijuana for PONV
The study included patients undergoing surgical procedures (gynecological or breast surgery) associated with a high risk of PONV. Patients were randomly assigned to receive a "relatively high" dose of intravenous THC or an inactive placebo. Both treatments were given toward the end of surgery, before emergence from general anesthesia.
Rates of PONV were compared between groups. The original study design called for enrollment of about 300 patients, to detect a "clinically significant" 25 percent relative reduction in PONV—the estimated effect of current medications to prevent nausea and vomiting (antiemetics).
However, the trial was halted after the first 40 patients because of "clinically unacceptable" side effects of THC, as well as questionable effects on PONV. In both the THC and placebo groups, about 60 to 70 percent of patients experienced PONV during the first 24 hours after emerging from anesthesia.
The relative risk reduction with THC was just 12 percent—well under the clinically significant cutoff point. The effect was even weaker after adjustment for differences in anesthesia time.
Meanwhile, there were major problems with side effects. Patients receiving THC took longer to emerge from anesthesia, were more sedated after emergence, and tended to remain in the recovery room longer. The THC group needed less pain medication for the first few hours, possibly because of their increased sedation.
Mental or mood (psychotropic) side effects were "unpredictable in both quantity and quality" in the THC group. "Patients' satisfaction varied enormously from 'best anesthesia ever' to 'worst experience of my life,'" the researchers add.
Nausea and vomiting after surgery is a common problem that can lead to serious complications. Current antiemetic drugs can reduce but not eliminate PONV. Past reports have suggested that marijuana compounds (cannabinoids) may prevent nausea and vomiting during cancer chemotherapy.
Marijuana extracts have also been suggested for prevention of PONV, but the evidence is "very limited and inconclusive." Most previous studies have used synthetic oral cannabinoids, with conflicting results.
Dr. Theiler and colleagues conclude, "Due to an unacceptable side effect profile and uncertain antiemetic effects, intravenous THC administered at the end of surgery prior to emergence from anesthesia cannot be recommended for the prevention of PONV in high-risk patients." The researchers note several limitations of their study, including questions about the best dose and timing of THC administration.
About Anesthesia & Analgesia
Anesthesia & Analgesia was founded in 1922 and was issued bi-monthly until 1980, when it became a monthly publication. A&A is the leading journal for anesthesia clinicians and researchers and includes more than 500 articles annually in all areas related to anesthesia and analgesia, such as cardiovascular anesthesiology, patient safety, anesthetic pharmacology, and pain management. The journal is published on behalf of the IARS by Lippincott Williams & Wilkins (LWW), a division of Wolters Kluwer Health.
About the IARS
The International Anesthesia Research Society is a nonpolitical, not-for-profit medical society founded in 1922 to advance and support scientific research and education related to anesthesia, and to improve patient care through basic research. The IARS contributes nearly $1 million annually to fund anesthesia research; provides a forum for anesthesiology leaders to share information and ideas; maintains a worldwide membership of more than 15,000 physicians, physician residents, and others with doctoral degrees, as well as health professionals in anesthesia related practice; sponsors the SmartTots initiative in partnership with the FDA; supports the resident education initiative OpenAnesthesia; and publishes two journals, Anesthesia & Analgesia and A&A Case Reports.
About Wolters Kluwer
Wolters Kluwer is a global leader in professional information services. Professionals in the areas of legal, business, tax, accounting, finance, audit, risk, compliance and healthcare rely on Wolters Kluwer's market leading information-enabled tools and software solutions to manage their business efficiently, deliver results to their clients, and succeed in an ever more dynamic world.
Wolters Kluwer reported 2014 annual revenues of €3.7 billion. The group serves customers in over 170 countries, and employs over 19,000 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands. Wolters Kluwer shares are listed on NYSE Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY).
Wolters Kluwer Health is a leading global provider of information and point of care solutions for the healthcare industry. For more information about our products and organization, visit www.wolterskluwerhealth.com, follow @WKHealth or @Wolters_Kluwer on Twitter, like us on Facebook, follow us on LinkedIn, or follow WoltersKluwerComms on YouTube.